Cystatin C assay kit (latex enhanced immune nephelometry)

For in vitro quantitative determination of serum cystatin C

【Clinical significance】

Glomerular filtration (GFR) is the most direct indicator to detect renal function. Cystatin C is a low-molecular-weight cysteine protease inhibitor, who can be stably produced in all nucleated cells. Cystatin C was nearly completely filtered by GFR and reabsorbed by renal tubules with neither secretion nor excretion. Cystatin C is not affected by inflammation, gender, and age-related changes in muscle, so Cystatin C is a very stable indicator to reflect glomerular filtration, which is applicable for early-stage evaluation of renal dysfunction and recovery judgment of renal transplant patients.

【Test principle】

Mix serum (containing CYS-C) and reagent (goat anti-human polyclonal antibody sensitized CYS-C nanospheres) to form insoluble immune complexes, which increases the turbidity of reaction solution.
Measure absorbance by spectrophotometer at the wavelength of 546nm.
The turbidity reflects the concentration of CYS-C in the sample, which can be read out by a working curve calibrated by standard serum.

【Storage conditions and validity】

Stable for one year when stored at 2 ~ 8 ℃ in the dark (freeze prohibited),
Stable at 2~8 °C for one month after initial use.


1. The amount of reagent and sample might need to increase or decrease under the same proportion to meet the requirement of biochemical analytical instruments.
2. When the samples β2-MG concentration exceeds 150.0mg/L, dilute with 0.9% saline for a maximum of 10 times and test again.
3. 0.05% Proclin-300 is contained as a preservative. NO SWALLOW and avoid contact with skin and mucous membranes. If you accidentally contact with skin or mucous membranes, rinse immediately with plenty of water and go to hospital for treatment.
4. Sheep-derived antibodies are included, which is a potential risk of infection. NO SWALLOW and avoid contact with skin and mucous membranes.


April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.